CL2015000816A1 - Compuestos derivados de piridinonas; composicion farmaceutica; un metodo para tratar una condicion fibrotica. - Google Patents

Compuestos derivados de piridinonas; composicion farmaceutica; un metodo para tratar una condicion fibrotica.

Info

Publication number
CL2015000816A1
CL2015000816A1 CL2015000816A CL2015000816A CL2015000816A1 CL 2015000816 A1 CL2015000816 A1 CL 2015000816A1 CL 2015000816 A CL2015000816 A CL 2015000816A CL 2015000816 A CL2015000816 A CL 2015000816A CL 2015000816 A1 CL2015000816 A1 CL 2015000816A1
Authority
CL
Chile
Prior art keywords
pyridinones
treat
pharmaceutical composition
compounds derived
fibrotic condition
Prior art date
Application number
CL2015000816A
Other languages
English (en)
Inventor
Brad Owen Buckman
John Beamond Nicholas
Johnnie Y Ramphal
Kumaraswamy Emayan
Scott D Seiwert
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000816(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CL2015000816A1 publication Critical patent/CL2015000816A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2015000816A 2012-10-02 2015-04-01 Compuestos derivados de piridinonas; composicion farmaceutica; un metodo para tratar una condicion fibrotica. CL2015000816A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709075P 2012-10-02 2012-10-02
US201361777499P 2013-03-12 2013-03-12
US201361872157P 2013-08-30 2013-08-30

Publications (1)

Publication Number Publication Date
CL2015000816A1 true CL2015000816A1 (es) 2015-08-28

Family

ID=50435378

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000816A CL2015000816A1 (es) 2012-10-02 2015-04-01 Compuestos derivados de piridinonas; composicion farmaceutica; un metodo para tratar una condicion fibrotica.

Country Status (35)

Country Link
US (5) US9359379B2 (es)
EP (1) EP2903991B1 (es)
JP (2) JP6326053B2 (es)
KR (2) KR102176667B1 (es)
CN (2) CN104822687B (es)
AR (1) AR092742A1 (es)
AU (2) AU2013327505B2 (es)
BR (1) BR112015006341B1 (es)
CA (3) CA3147961A1 (es)
CL (1) CL2015000816A1 (es)
CO (1) CO7350637A2 (es)
CR (1) CR20150225A (es)
DK (1) DK2903991T3 (es)
EA (2) EA027120B1 (es)
EC (1) ECSP15017109A (es)
ES (1) ES2835331T3 (es)
HR (1) HRP20201934T1 (es)
HU (1) HUE051581T2 (es)
IL (3) IL237629B (es)
LT (1) LT2903991T (es)
MX (2) MX375381B (es)
MY (1) MY174897A (es)
NZ (2) NZ745814A (es)
PE (2) PE20151415A1 (es)
PH (1) PH12015500735A1 (es)
PL (1) PL2903991T3 (es)
PT (1) PT2903991T (es)
RS (1) RS61225B1 (es)
SA (1) SA515360217B1 (es)
SG (1) SG11201501751RA (es)
SI (1) SI2903991T1 (es)
TW (2) TWI734049B (es)
UA (1) UA120908C2 (es)
WO (1) WO2014055548A1 (es)
ZA (1) ZA201502457B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
IN2014DN09346A (es) 2012-06-13 2015-07-17 Hoffmann La Roche
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9315464B1 (en) 2013-01-31 2016-04-19 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
EP3157921A1 (en) * 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
WO2016077375A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3250571B1 (en) 2015-01-29 2022-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
WO2017024408A1 (en) 2015-08-11 2017-02-16 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN108137539B (zh) 2015-08-12 2022-01-11 尼奥迈德研究所 取代的苯并咪唑、它们的制备和它们作为药物的用途
CN105085383B (zh) * 2015-08-19 2017-09-01 四川大学 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
AU2016341259B2 (en) * 2015-10-22 2019-09-12 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
KR20180079328A (ko) * 2015-11-04 2018-07-10 이데미쓰 고산 가부시키가이샤 벤즈이미다졸 축합 헤테로아릴
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
CN105732497B (zh) * 2016-02-02 2019-02-01 浙江工业大学 2-芳基-4-甲基环并吡啶-1(2h)-酮类衍生物及其合成方法与应用
CN105541715B (zh) * 2016-02-02 2019-04-09 浙江工业大学 多取代吡啶-1(2h)-酮衍生物及其合成方法与应用
RU2738844C2 (ru) * 2016-04-14 2020-12-17 Гуанчжоу Джойо Фарматек Ко., Лтд Содержащее заместитель, представляющий собой бутан, в гетероциклическом кольце производное пиридона для лечения фиброза и воспалительных заболеваний
CA3018802A1 (en) 2016-04-15 2017-10-19 Abbvie Inc. Bromodomain inhibitors
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN107698498A (zh) * 2016-08-08 2018-02-16 罗楹 一种羟尼酮的制备方法
CN107698499A (zh) * 2016-08-08 2018-02-16 罗楹 一种羟尼酮的制备方法
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
US11207304B2 (en) 2016-11-30 2021-12-28 Genentech, Inc. Methods of administering anti-fibrotic therapy
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
WO2019028062A1 (en) * 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3459939A1 (en) * 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
US11198686B2 (en) 2017-10-13 2021-12-14 Guangzhou Joyo Pharmatech Co., Ltd. Crystal form and salt form of pyridone compound and preparation method therefor
TWI834634B (zh) * 2018-02-02 2024-03-11 美商建南德克公司 醫藥化合物、其鹽類、其製劑及其等之製備和使用之方法
AU2019309894A1 (en) 2018-07-27 2021-01-28 Biotheryx, Inc. Bifunctional compounds as CDK modulators
US11171132B2 (en) * 2019-10-03 2021-11-09 Globalfoundries U.S. Inc. Bi-directional breakdown silicon controlled rectifiers
KR20220109439A (ko) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
JP7584623B2 (ja) * 2020-07-23 2024-11-15 シトシンラボ セラピューティクス カンパニー， リミテッド キナーゼ阻害活性を有する化合物
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
WO2022242769A1 (zh) * 2021-05-20 2022-11-24 广州嘉越医药科技有限公司 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用
CN113234013B (zh) * 2021-05-21 2022-05-24 杭州医学院 一种抑制胶原合成和沉积的化合物及其应用
KR20240133695A (ko) * 2021-12-10 2024-09-04 프로테나 바이오사이언시즈 리미티드 Dyrk1a 억제제로서의 헤테로시클릭 화합물
CN116332947A (zh) * 2021-12-24 2023-06-27 上海海和药物研究开发股份有限公司 具有mat2a抑制活性的嘧啶-2(1h)-酮并二环类化合物及其用途
CN116514803A (zh) * 2022-01-21 2023-08-01 上海赛岚生物科技有限公司 一种激酶抑制剂的盐晶型和自由碱晶型
CN115925624B (zh) * 2022-12-12 2025-06-27 浙江工业大学 N-芳基-多元环并[c]-2-吡啶酮衍生物、合成方法及其应用
WO2025209440A1 (zh) * 2024-04-02 2025-10-09 广州嘉越医药科技有限公司 一种吡啶酮衍生物的药物组合物及其应用

Family Cites Families (558)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE149666C (es)
DE1070639B (de) 1959-12-10 Farbenfabriken Bayer Aktiengesellschaft, Levenkusen-Bayerwerk Verfahren zur Herstellung von Peptiderj
CH312531A (de) 1952-06-20 1955-12-31 Ciba Geigy Verfahren zur Herstellung eines Pyridazons.
CH312530A (de) 1952-06-20 1955-12-31 Ciba Geigy Verfahren zur Herstellung eines Pyridazons.
GB788393A (en) 1953-04-30 1958-01-02 Ciba Ltd Process for the manufacture of pyridazone compounds
CH333366A (de) 1953-09-04 1958-10-15 Ciba Geigy Verfahren zur Herstellung neuer Pyridazone
DE1070639C2 (es) 1958-09-30 1964-04-16
US3014034A (en) 1959-01-22 1961-12-19 Ciba Pharm Prod Inc 1, 3-diaryl, 5-amino-pyridazinones
GB889317A (en) 1959-01-22 1962-02-14 Ciba Ltd New phenyl-diazines and a process for their manufacture
JPS422264Y1 (es) 1966-08-10 1967-02-10
US3622340A (en) 1968-08-12 1971-11-23 Eastman Kodak Co 4-thiouracil compounds as fog inhibitors
US3644375A (en) * 1968-10-18 1972-02-22 Toray Industries Lactam dicarboxylic acids and process for producing them
GB1237031A (en) * 1969-03-07 1971-06-30 Toray Industries Lactam dicarboxylic acids and a process for their production
UST866035I4 (en) 1969-05-05 1969-09-30 Defensive publication
FR2081572B1 (es) * 1970-03-12 1973-04-06 Rhone Poulenc Sa
BE787523A (fr) 1971-08-13 1973-02-12 Chem Pharmac Fabrik Dr Hermann Medicament a base de pyridone-2
DE2143744A1 (de) 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-one und verfahren zu ihrer herstellung
ES421598A1 (es) 1972-12-18 1977-01-01 Affiliated Med Res Un procedimiento para la sintesis de piridonas.
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
AT333774B (de) 1974-09-24 1976-12-10 Chemie Linz Ag Verfahren zur herstellung von 3-phenylpyridazonen
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
DE2557342A1 (de) 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4258052A (en) 1976-08-17 1981-03-24 Yu Ruey J Treatment of psoriasis with nicotinamide analogues
DE2707268A1 (de) 1977-02-19 1978-08-31 Hoechst Ag Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung
GB1596887A (en) 1977-07-15 1981-09-03 Rohm & Haas 2-pyridone derivatives and their use as plant growth regulators
JPS557201A (en) 1978-05-23 1980-01-19 Shionogi & Co Ltd Derivative of tetrahydrothiopyrano(2,3-b)indole
GB2042562B (en) 1979-02-05 1983-05-11 Sandoz Ltd Stabilising polymers
DD149666A1 (de) 1979-06-27 1981-07-22 Karl Gewald Verfahren zur herstellung von 6-amino-und 6-hydroxy-1-aryl-5-cyan-2(1h)-pyridinonen und-thionen
JPS5721388A (en) 1980-07-11 1982-02-04 Nippon Nohyaku Co Ltd Condensed pyrazole derivative
JPS5777671A (en) 1980-10-31 1982-05-15 Yasumitsu Tamura Preparation of hydroxyindoles ( or 1,4-dihydroisoquinolones) and their intermediate
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4476307A (en) 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US4473696A (en) 1982-10-07 1984-09-25 Ici Americas Inc. Synthesis of 2-substituted-5-methyl-pyridines
US4645839A (en) 1982-12-17 1987-02-24 Ici Americas Inc. Sulphur dehydrogenation process to yield 5-methyl-2-pyridone
US4650804A (en) 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
US4576942A (en) 1984-07-12 1986-03-18 Usv Pharmaceutical Corp. Anti-allergic and anti-inflammatory bi- and tri- cyclo-1,4-thiazine derivatives, composition, and method of use therefor
EP0180188B1 (en) * 1984-10-30 1992-04-15 Otsuka Pharmaceutical Co., Ltd. A composition for increasing the anti-cancer activity of an anti-cancer compound
EP0323441B1 (en) * 1984-10-30 1996-04-24 Otsuka Pharmaceutical Co., Ltd. 5-Fluorouracil derivatives
JPS6256187A (ja) 1985-09-05 1987-03-11 Ricoh Co Ltd 感熱記録材料
US5173489A (en) 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
US4760083A (en) 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
DE3805746C2 (de) 1987-03-05 2003-04-10 Clariant Finance Bvi Ltd 1:2-Chromkomplexfarbstoffe
JPS63290821A (ja) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
DK641487A (da) 1987-12-07 1989-06-08 Gluetech Aps Fremgangsmaade til modificering af polymeroverflader
DE3807295A1 (de) 1988-03-05 1989-09-14 Basf Ag Neue n-heteroaryl-tetrahydrophthalimidverbindungen
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
JPH022264A (ja) 1988-06-14 1990-01-08 Canon Inc メツセージ通信システム
US5019365A (en) 1988-11-29 1991-05-28 The Dow Chemical Company Quaternary polyamines as sulfite oxidation inhibitors
US5167941A (en) 1988-11-29 1992-12-01 The Dow Chemical Company Quaternary polyamines as sulfite oxidation inhibitors in amine scrubbing of SO2
GB8901836D0 (en) 1989-01-27 1989-03-15 Sobio Lab Compounds
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5077142A (en) 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
JPH0343744A (ja) 1989-07-12 1991-02-25 Hitachi Chem Co Ltd 電子写真感光体
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
CA2078126A1 (en) 1990-03-27 1991-09-28 Jerry Leroy Adams 5-lipoxygenase inhibitors
JPH0444235A (ja) 1990-06-08 1992-02-14 New Japan Radio Co Ltd 高速バイポーラトランジスタの製造方法
JPH0449567A (ja) 1990-06-19 1992-02-18 Matsushita Electric Ind Co Ltd 磁気記録再生装置
ES2131506T3 (es) 1990-09-21 1999-08-01 Rohm & Haas Dihidropiridacinonas y piridacinonas como fungicidas.
JPH04223457A (ja) 1990-12-26 1992-08-13 Konica Corp ハロゲン化銀写真感光材料
AU1191292A (en) 1991-02-11 1992-09-07 Schering Agrochemicals Limited Imidazole pesticides
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586523A4 (en) 1991-05-15 1995-11-29 Univ Yale Determination of prodrugs metabolizable by the liver and therapeutic use thereof
JPH0519023A (ja) 1991-07-11 1993-01-26 Hitachi Ltd 集積回路装置
EP0531578B1 (en) 1991-09-10 1995-12-20 Agfa-Gevaert N.V. Thermally transferable fluorescent compounds
ES2113399T3 (es) 1991-12-26 1998-05-01 Mitsubishi Chem Corp Derivados de beta-oxo-beta-bencenopropano-tio-amida.
US5241065A (en) 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
WO1993021185A1 (en) 1992-04-16 1993-10-28 The Du Pont Merck Pharmaceutical Company Substituted nitrogen containing spiro compounds for use in treating cognitive deficits
WO1993023404A1 (en) 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
DE4237656A1 (de) 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
US5459269A (en) * 1992-06-18 1995-10-17 North Carolina State University 14-halo-camptothecins
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
CA2099743A1 (en) 1992-07-02 1994-01-03 Akihiko Ishida Pyridazinone derivatives and processes for preparing the same
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5356904A (en) 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
DE4242451A1 (de) 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
AU5891494A (en) 1993-01-29 1994-08-15 Nippon Soda Co., Ltd. Heterocyclic derivative
JPH06256187A (ja) 1993-03-02 1994-09-13 Fujisawa Pharmaceut Co Ltd キノリジノン化合物またはその塩を含有する鎮咳・去痰剤
JPH08510251A (ja) 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法
JP3507124B2 (ja) 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
DE4423934A1 (de) 1993-09-02 1995-03-09 Basf Ag 3(2H)-Pyridazinon-Derivate, Verfahren zu ihrer Herstellung und Verwendung
TW403741B (en) 1993-10-15 2000-09-01 Takeda Chemical Industries Ltd Triazine derivative, production and use thereof
JPH07128793A (ja) 1993-11-05 1995-05-19 Konica Corp 染料の固体微粒子分散物および該分散物を含有するハロゲン化銀写真感光材料
CA2153498A1 (en) 1993-11-10 1995-05-18 Hidetsura Cho Chroman derivative and medicinal use thereof
WO1995016712A1 (en) 1993-12-15 1995-06-22 Smithkline Beecham Corporation Compounds and methods
JPH07233072A (ja) 1993-12-28 1995-09-05 Tanabe Seiyaku Co Ltd 医薬組成物
AU694157B2 (en) 1993-12-29 1998-07-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
JP3781200B2 (ja) 1994-04-27 2006-05-31 コニカミノルタホールディングス株式会社 ハロゲン化銀写真感光材料の処理方法
JP3261641B2 (ja) 1994-04-28 2002-03-04 コニカ株式会社 ハロゲン化銀写真感光材料の処理方法
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
JP2794392B2 (ja) 1994-07-22 1998-09-03 大同テック株式会社 高圧ガス容器の保守装置
JPH08134371A (ja) 1994-11-02 1996-05-28 Konica Corp 固体微粒子分散物及びハロゲン化銀写真感光材料及び画像形成方法
EP0717143A1 (de) 1994-12-16 1996-06-19 Lignozym GmbH Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
JPH11501911A (ja) 1995-03-03 1999-02-16 ビー マーゴリン、ソロモン サイトカイン成長因子の引き起こす疾病の治療
US6114353A (en) 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US5869428A (en) 1995-03-13 1999-02-09 Ishihara Sangyo Kaisha Ltd. Pyridonesulfonylurea compounds, process for their production and herbicides containing them
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
WO1996033994A1 (en) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Amino-substituted derivatives, process for the preparation thereof, and herbicide
DE19520613A1 (de) 1995-06-06 1996-12-12 Bayer Ag Phenylpyridazinone
JPH0933072A (ja) 1995-07-18 1997-02-07 Hitachi Ltd 蓄熱水槽及びマルチ氷蓄熱ユニット
WO1997005109A1 (en) 1995-07-31 1997-02-13 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5945417A (en) 1995-07-31 1999-08-31 Novo Nordisk Heterocyclic compounds, their preparation and use
AU723064B2 (en) 1995-08-25 2000-08-17 Dow Agrosciences Llc Compositions having synergistic fungitoxic effects
EP0866656B1 (en) 1995-09-19 2007-04-25 MARGOLIN, Solomon B. Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors
US5962478A (en) 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
DE19535501A1 (de) 1995-09-25 1997-03-27 Bayer Ag Pyridonmethidazofarbstoffe
JPH0995165A (ja) 1995-09-29 1997-04-08 Tachi S Co Ltd シートの前後チルト機構
JPH0995166A (ja) 1995-10-02 1997-04-08 Tatsuya Mikami 乗物用座席
JPH09249567A (ja) 1996-01-12 1997-09-22 Otsuka Pharmaceut Co Ltd 医薬組成物
JPH09204932A (ja) 1996-01-25 1997-08-05 Fujitsu Ltd リチウム二次電池用電解液及びリチウム二次電池
IT1286545B1 (it) 1996-02-09 1998-07-15 Antonio Guarna Derivati benzo(c) chinolizinici,loro preparazione ed uso come inibitori delle 5-alfa-riduttasi
JPH09244235A (ja) 1996-03-14 1997-09-19 Toshiba Corp アルカリ現像用レジスト
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
JP2000510444A (ja) 1996-03-29 2000-08-15 メルク フロスト カナダ アンド カンパニー シクロオキシゲナーゼ抑制剤としてのビスアリールシクロブテン誘導体
JPH09319023A (ja) 1996-05-27 1997-12-12 Fuji Photo Film Co Ltd 感熱記録材料
EP0906307B1 (en) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
EP0929543B1 (en) 1996-09-26 2001-10-31 Syngenta Participations AG Herbicidal composition
US6121251A (en) 1996-10-11 2000-09-19 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19754348A1 (de) 1996-12-11 1998-06-18 Ciba Geigy Ag Neue Herbizide
EP0951285A1 (en) 1996-12-30 1999-10-27 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
DE19708928A1 (de) 1997-03-05 1998-09-10 Bayer Ag Substituierte aromatische Aminoverbindungen
DE19821263A1 (de) 1997-05-12 1998-11-19 Call Krimhild Enzymatisches Bleichsystem mit enzymwirkungsverstärkenden Verbindungen zur Behandlung von Textilien
AU8331698A (en) 1997-05-12 1998-12-08 Call, Krimhild Enzymatic bleaching system containing new compounds for intensifying enzymatic action
JP3043744U (ja) 1997-05-26 1997-11-28 株式会社新和 バッグ
DE19726241A1 (de) 1997-06-20 1998-12-24 Call Krimhild Erweitertes enzymatisches Multikomponentensystem zur Behandlung von Abwässern, zur Herstellung von Holzverbundstoffen, zum Deinken von Altpapier, Colour stripping von Altpapier, zum Einsatz als Oxidationssystem bei der organischen Synthese und zum Einsatz bei der Kohleverflüssigung
DE19729061A1 (de) 1997-07-08 1999-01-14 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
SE9702651D0 (sv) 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
SE9702794D0 (sv) 1997-07-24 1997-07-24 Astra Pharma Prod New compounds
DE19731784A1 (de) 1997-07-24 1999-02-04 Bayer Ag Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide
JPH1149755A (ja) 1997-07-30 1999-02-23 Nippon Kayaku Co Ltd 新規含窒素ヘテロ環誘導体およびそれを有効成分とする殺虫殺ダニ組成物
ITFI970193A1 (it) 1997-08-01 1999-02-01 Applied Research Systems Uso di derivati benzo(c) chinolizinici come regolatori della crescita delle piante e composizioni ad uso agricolo che contengono tali
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
CA2299300C (en) 1997-08-22 2007-04-17 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
PT1005460E (pt) 1997-08-22 2006-07-31 Abbott Lab Biossintese de inibidores de prostaglandina-endoperoxido h-sintase
EP1015429B1 (en) 1997-09-09 2004-05-12 Bristol-Myers Squibb Pharma Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
EP1030843A4 (en) 1997-10-27 2002-11-06 Isk Americas Inc SUBSTITUTED BENZENE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND HERBICIDES AND LEAVING COMPOSITIONS THAT CONTAIN THEM
ATE213242T1 (de) 1997-11-21 2002-02-15 Astrazeneca Uk Ltd Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren
JPH11180952A (ja) 1997-12-19 1999-07-06 Maruho Co Ltd ２−オキシインドール誘導体
ES2304797T3 (es) 1997-12-19 2008-10-16 Amgen Inc. Compuestos de piridina y piridazina sustituidos y su uso farmaceutico.
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
AU2108099A (en) * 1998-01-30 1999-08-16 Procept, Inc. Immunosuppressive agents
DE19803667A1 (de) 1998-01-30 1999-08-05 Max Planck Gesellschaft Verfahren zur Herstellung von 5-Alkoxy (bzw. 5-Aroxy) -2,3-dihydrofuran-2-onen
FR2774986A1 (fr) 1998-02-16 1999-08-20 Rhodia Chimie Sa Utilisation de pyrone(s) ou equivalent pour masquer des isocyanates, procede de masquage, isocyanates ainsi masques, composition en contenant, procede de revetement utilisant ces compositions, revetement aini obtenu
AU755003B2 (en) 1998-03-17 2002-11-28 Solomon B. Margolin Topical antiseptic compositions and methods
CA2312953A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
BR9909548A (pt) 1998-04-09 2000-12-12 Bayer Ag Fenilpiridazinonas substituìdas
BR9909976A (pt) 1998-04-27 2000-12-26 Centre Nat Rech Scient Composto, processo para a obtenção de compostos, derivado litiado, composições farmacêuticas, e, processos de tratamento de doenças relacionadas com hiv e de tratamento de infecção de hiv
AU3536699A (en) 1998-04-27 1999-11-16 Ihara Chemical Industry Co. Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
CA2333947C (en) 1998-06-01 2010-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility
FR2779429B1 (fr) 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
DE69810518D1 (de) 1998-09-18 2003-02-06 Mepha Ag Aesch Topisch verabreichbare alkyl-, phenyl-pyridone-arzneimittel
WO2000025789A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis
JP3043744B1 (ja) 1999-03-17 2000-05-22 日本ピラー工業株式会社 単結晶ＳｉＣの育成方法
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
DE19918725A1 (de) 1999-04-24 2000-10-26 Bayer Ag Substituierte N-Cyano-sulfonsäureanilide
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
BR0010349B1 (pt) 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
FR2797629B1 (fr) 1999-08-19 2001-09-21 Rhodia Chimie Sa Utilisation de pyrone(s) ou equivalent pour masquer des isocyanates, procede de masquage, isocyanates ainsi masques, composition en contenant, procede de revetement utilisant ces compositions, revetement ainsi obtenu
AT408223B (de) 1999-12-27 2001-09-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von oxindolen
IL150650A0 (en) 2000-01-20 2003-02-12 Eisai Co Ltd Piperidine derivatives and pharmaceutical compositions containing the same
US20020019395A1 (en) 2000-02-01 2002-02-14 Bing-Yan Zhu Indalone and benzimidazolone inhibitors of factor Xa
US6777413B2 (en) 2000-02-01 2004-08-17 Millennium Pharmaceuticals, Inc. 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1257550T3 (da) 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
GB0002740D0 (en) 2000-02-07 2000-03-29 Novartis Ag Organic compounds
WO2001058448A1 (fr) 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Inhibiteur d'apoptose
TR200202033T2 (tr) 2000-02-21 2003-01-21 Cymar Inc. Epilepsi Tedavisi İçin Terkipler ve Yöntemler
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
US6548517B2 (en) 2000-03-24 2003-04-15 Millennium Pharmaceuticals, Inc. Oxindole inhibitors of factor Xa
DE10024938A1 (de) 2000-05-19 2001-11-22 Bayer Ag Substituierte Iminoazine
WO2001092188A1 (en) 2000-05-29 2001-12-06 Shionogi & Co., Ltd. Method for labeling with tritium
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
DE10034803A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Sulfonsäureanilide
JP4251868B2 (ja) 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
US20020049211A1 (en) 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
CA2742411A1 (en) 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
ATE319706T1 (de) 2000-09-19 2006-03-15 Centre Nat Rech Scient Pyridinon und pyridinethion-derivate mit hiv- hemmenden eigenschaften
CN1120151C (zh) 2000-10-24 2003-09-03 大连化学工业股份有限公司 制备内酰胺的方法
EP1337150A4 (en) 2000-10-27 2007-09-26 Dow Agrosciences Llc SUBSTITUTED 4,5-DIHYDRO-1,2,4-TRIAZIN-6-ONE, 1,2,4-TRIAZIN-6-ONE AND THEIR USE AS FUNGICIDES AND INSECTICIDES
US6670380B2 (en) 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
US7160912B2 (en) 2000-12-26 2007-01-09 Dr.Reddy's Laboratories Ltd. Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them
ES2330719T3 (es) 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
KR100891887B1 (ko) 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제
US20040122223A1 (en) * 2001-02-07 2004-06-24 Davis Jeremy Martin Non-natural nucleotides and dinucleotides
DE10108995A1 (de) 2001-02-23 2002-09-05 Abbott Gmbh & Co Kg Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
WO2002085858A1 (en) 2001-04-20 2002-10-31 Asahi Glass Company, Limited Process for producing purified piperidine derivative
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
AU2002316180A1 (en) 2001-06-01 2002-12-16 The Regents Of The University Of California Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
JP4180254B2 (ja) 2001-06-29 2008-11-12 独立行政法人科学技術振興機構 窒素含有６員環の製造方法
JP2003021901A (ja) 2001-07-05 2003-01-24 Fuji Photo Film Co Ltd 感光性平版印刷版の光重合方法
WO2003014087A1 (fr) 2001-08-06 2003-02-20 Asahi Glass Company, Limited Procede de preparation de 5-methyl-1-phenyl-2(1h)-pyridinone
WO2003035650A1 (en) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
TWI330183B (es) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
CN1257901C (zh) 2001-11-08 2006-05-31 中国科学院上海药物研究所 一类四氢喹啉酮哌啶类化合物及其制备方法和用途
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB0129391D0 (en) 2001-12-07 2002-01-30 Syngenta Participations Ag Microbiocidal n-phenyl-n-[4-(4-pyridyl)-2-pyrimidin-2-yl]-amine derivatives
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
AU2003209321A1 (en) 2002-01-18 2003-07-30 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
RS52392B (sr) 2002-02-14 2013-02-28 Pharmacia Corporation Supstituisani piridinoni kao modulatori p38 map kinaze
JP2003238611A (ja) 2002-02-18 2003-08-27 Japan Polyolefins Co Ltd オレフィン類重合用触媒成分、オレフィン類重合用触媒及びポリオレフィン類の製造方法
PT1477186E (pt) 2002-02-19 2010-02-11 Shionogi & Co Antipruriginosos
JP2003261535A (ja) 2002-03-08 2003-09-19 Mitsubishi Chemicals Corp ２−ヒドロキシ−５−メチルピリジンの製造方法
MXPA04008822A (es) 2002-03-14 2004-11-26 Bayer Healthcare Ag Aroilpiridinonas monociclicas.
WO2003082265A2 (en) 2002-04-02 2003-10-09 Fujisawa Pharmaceutical Co Pharmaceutical composition for treating or preventing virus infectious diseases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2005530788A (ja) 2002-05-13 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類
JP2004043458A (ja) 2002-05-22 2004-02-12 Kyorin Pharmaceut Co Ltd ４−アリール−５−ヒドロキシイソキノリン誘導体およびその製造法
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CA2488635C (en) 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
US20040006135A1 (en) 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US7317014B2 (en) 2002-07-22 2008-01-08 Orchid Research Laboratories, Ltd. Bio-active pyrimidine molecules
MXPA05000983A (es) * 2002-07-24 2005-08-18 Kyorin Seiyaku Kk Derivados de 4-(aril substituido)-5-hidroxiisoquinolinona.
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
WO2004014892A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
EP1551369A4 (en) 2002-08-28 2007-05-09 Intermune Inc COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES
AU2003264386A1 (en) 2002-09-10 2004-04-30 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
EP1558606A4 (en) 2002-10-02 2008-05-07 Bristol Myers Squibb Co DIAMINOALKYL CONTAINING LACTAM, BETA AMINO ACIDS, ALPHA AMINO ACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
WO2004035563A1 (en) * 2002-10-17 2004-04-29 Syngenta Participations Ag 3-heterocyclylpyridine derivatives useful as herbicides
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20040142950A1 (en) 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US20040157738A1 (en) 2003-02-12 2004-08-12 Ishihara Sangyo Kaisha, Ltd. Novel oxygen containing fused cyclic derivatives and herbicidal, desiccant and defoliate compositions containing them
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PL378111A1 (pl) 2003-02-14 2006-03-06 Smithkline Beecham Corporation Nowe związki
US7012088B2 (en) 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
WO2004078174A1 (en) 2003-02-28 2004-09-16 Morgan Lee R Resonance modulator for diagnosis and therapy
WO2005013917A2 (en) 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
JP2004269469A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
WO2004089914A1 (de) 2003-04-08 2004-10-21 Basf Aktiengesellschaft Benzolsulfonamid-derivate als herbizide oder desikkante/defoliante verbindungen
JP4089491B2 (ja) 2003-04-14 2008-05-28 コニカミノルタホールディングス株式会社 重合開始剤、重合組成物、ラジカル発生方法、平版印刷版材料および平版印刷版の作製方法
WO2004110245A2 (en) 2003-05-16 2004-12-23 Intermune, Inc. Combination therapy for cancer treatment
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
US20070092488A1 (en) 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
JP2004359641A (ja) 2003-06-06 2004-12-24 Ono Pharmaceut Co Ltd Ｃｃｒ５活性化剤
EP1641804A1 (en) 2003-06-20 2006-04-05 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
AU2004249498B2 (en) 2003-06-20 2009-11-19 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
US20050153941A1 (en) 2003-06-27 2005-07-14 Tomoyuki Miyabayashi Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line
JP2005013152A (ja) 2003-06-27 2005-01-20 Asahi Kasei Corp 細胞分化抑制剤及びこれを用いた細胞培養方法、培養液、培養された細胞
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
CA2529510A1 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005007632A1 (en) 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
WO2005023246A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
WO2005030751A2 (en) 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
DE10345648A1 (de) 2003-10-01 2005-04-21 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von TMC-69-6H und verwandten Pyridonderivaten und deren Verwendung als Phosphatase-Inhibitoren
WO2005039598A1 (en) 2003-10-24 2005-05-06 Intermune, Inc. Method of treating alcoholic liver disease
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
JP4614884B2 (ja) 2003-11-14 2011-01-19 シャンハイ ゲノミックス インク ピリドンの誘導体とその使用
JP4170198B2 (ja) 2003-11-14 2008-10-22 一丸ファルコス株式会社 化粧料組成物
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US20070105890A1 (en) * 2003-11-26 2007-05-10 Dainippon Sumitomo Pharma Co., Ltd Novel condensed imidazole derivative
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
ES2299995T3 (es) 2004-01-29 2008-06-01 Pfizer, Inc. Derivados de 1-isopropil-2-oxo-1,2-dihidropiridina-3-carboxamida con actividad agonista de receptor 5-ht4.
JP2005255675A (ja) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
GB0402812D0 (en) 2004-02-09 2004-03-10 Tanabe Seiyaku Co Novel compounds
US7872123B2 (en) 2004-02-20 2011-01-18 Japan Science And Technology Agency Process of making α-aminooxyketone/α-aminooxyaldehyde and α-hydroxyketone/α-hydroxyaldehyde compounds and a process making reaction products from cyclic α,β-unsaturated ketone substrates and nitroso substrates
WO2005085200A1 (ja) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. ピリドン誘導体
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
MY143245A (en) 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
JPWO2005105743A1 (ja) 2004-04-28 2008-03-13 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
DE102004028973A1 (de) * 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
WO2006011024A2 (en) 2004-07-19 2006-02-02 Glenmark Pharmaceuticals Ltd. New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
US20080171755A1 (en) 2004-08-31 2008-07-17 Wen-Cherng Lee Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7694674B2 (en) 2004-09-21 2010-04-13 Carleton Life Support Systems, Inc. Oxygen generator with storage and conservation modes
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
US20060069260A1 (en) 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
JP4223457B2 (ja) 2004-10-06 2009-02-12 本田技研工業株式会社 車両の電動ステアリング装置
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
US20060142348A1 (en) 2004-10-12 2006-06-29 Decode Chemistry, Inc. Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
TW200843761A (en) 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
US7713998B2 (en) 2004-11-10 2010-05-11 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
JP2006142666A (ja) 2004-11-19 2006-06-08 Mitsubishi Chemicals Corp 光学記録媒体用色素
WO2006055918A2 (en) 2004-11-19 2006-05-26 Pharmacopeia Drug Discovery, Inc. One-dimensional qsar models
CN101048383A (zh) 2004-11-23 2007-10-03 惠氏公司 促性腺激素释放激素受体拮抗剂
ATE543803T1 (de) 2004-11-24 2012-02-15 Vertex Pharma 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
WO2006056427A1 (en) 2004-11-24 2006-06-01 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
US20080255134A1 (en) 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
WO2006059778A1 (ja) 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. 置換ピリドン誘導体
TW200635596A (en) 2004-12-17 2006-10-16 Anadys Pharmaceuticals Inc Pyridazinone compounds
JP4864009B2 (ja) 2004-12-23 2012-01-25 姚▲輝▼ ピリミジノン化合物とその調製法及び用途
CN101090889A (zh) * 2004-12-29 2007-12-19 纳幕尔杜邦公司 荆芥内酰胺及其n－取代衍生物
US20060148842A1 (en) * 2004-12-29 2006-07-06 Scialdone Mark A Nepetalactams and N-substituted derivatives thereof
CA2592066A1 (en) * 2004-12-29 2006-07-06 E.I. Du Pont De Nemours And Company Dihydronepetalactams and n-substituted derivatives thereof
CN101090890A (zh) * 2004-12-29 2007-12-19 纳幕尔杜邦公司 二氢荆芥内酰胺及其n－取代衍生物
JP2008527002A (ja) 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
WO2006079021A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20080119518A1 (en) * 2005-02-04 2008-05-22 Yuichi Suzuki 1-(Piperidin-4- Yl)-1H-Indole Derivatives
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
CN1676518B (zh) 2005-03-17 2010-05-12 南开大学 4-取代苯基哒嗪类化合物及除草活性
US20060270709A1 (en) 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches
AU2006234627C1 (en) 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
CN1846699A (zh) 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
NZ563448A (en) 2005-04-28 2011-01-28 Boehringer Ingelheim Int Benzofuranone derivatives for treating inflammatory diseases
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
GB0511190D0 (en) 2005-06-01 2005-07-06 Sterix Ltd Use
US8350043B2 (en) 2005-06-07 2013-01-08 Pharmacopeia, Inc. Azinone and diazinone V3 inhibitors for depression and stress disorders
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
US7781475B2 (en) 2005-06-10 2010-08-24 Merck Patent Gmbh Oxindoles as kinase inhibitors
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1896033A4 (en) 2005-06-15 2010-12-22 New York Blood Ct Inc ANTIVIRAL COMPOSITIONS WITH HETEROCYCLIC SUBSTITUTED PHENYLFURANES AND RELATED COMPOUNDS
WO2007008548A2 (en) 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007006591A2 (fr) 2005-07-13 2007-01-18 Bayer Cropscience Sa Dihalogenation d'hydroxipyridones n,o-disubstituees et leurs utilisations
JP2007063268A (ja) 2005-08-05 2007-03-15 Tanabe Seiyaku Co Ltd 医薬組成物
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
AU2006285599A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
RU2008112691A (ru) 2005-10-03 2009-10-10 Оно Фармасьютикал Ко., Лтд. (Jp) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
CA2626789A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
JP2007145819A (ja) 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
ES2351940T3 (es) 2005-11-18 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaindol-2-carboxamida.
EP1953147A1 (en) * 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
JP2009517390A (ja) 2005-11-23 2009-04-30 インターミューン インコーポレイテッド ストレス活性化プロテインキナーゼ系を調節する方法
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
WO2007072869A1 (ja) 2005-12-21 2007-06-28 Eisai R & D Management Co., Ltd. １，２－ジヒドロピリジン化合物の非晶質体
US20090088574A1 (en) 2005-12-21 2009-04-02 Eisai R&D Management Co., Ltd. Crystal of 1,2-dihydropyridine compound (type iv)
WO2007076104A1 (en) 2005-12-23 2007-07-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2636946A1 (en) 2006-01-11 2007-07-19 Merck And Co., Inc. Fused triazole tachykinin receptor antagonists
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
WO2007088876A1 (ja) 2006-02-02 2007-08-09 Kumiai Chemical Industry Co., Ltd. ピリドン誘導体及び除草剤
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
EP2004193A2 (en) 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN100396669C (zh) 2006-03-15 2008-06-25 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
JP5162574B2 (ja) 2006-03-22 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｄｍ２及びｐ５３間の相互作用のインヒビターとしての環式アルキルアミン誘導体
WO2007117482A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Renin inhibitors
WO2007117559A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Renin inhibitors
EP2010225A4 (en) 2006-04-13 2010-04-21 Cornell Res Foundation Inc METHOD AND COMPOSITIONS FOR C-REL TARGETING
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
ES2605727T3 (es) 2006-05-04 2017-03-16 Chroma Therapeutics Limited Inhibidores de MAP cinasa p38
MX2008014193A (es) 2006-05-05 2009-03-31 Millennium Pharm Inc Inhibidores del factor xa.
WO2007139150A1 (ja) 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
CN101484167B (zh) 2006-06-15 2012-07-04 上海睿星基因技术有限公司 吡啶酮类衍生物预防和治疗放射性肺损伤的用途
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP2046328A4 (en) 2006-07-19 2009-10-28 Univ Georgia Res Found PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY
ES2344760T3 (es) 2006-07-20 2010-09-06 Amgen Inc. Compuestos de piridona sustituidos y metodo de uso.
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
NZ574791A (en) 2006-08-02 2011-12-22 Lg Life Sciences Ltd Caspase inhibitors based on pyridazinone scaffold
JP4747985B2 (ja) 2006-08-02 2011-08-17 コニカミノルタオプト株式会社 光学フィルム、それを用いた偏光板及び液晶表示装置
KR20090047542A (ko) 2006-08-25 2009-05-12 베링거 인겔하임 인터내셔날 게엠베하 Ｍｃｈ 길항 활성을 갖는 신규한 피리돈 유도체 및 당해 화합물을 포함하는 의약
CN100516126C (zh) 2006-09-06 2009-07-22 北京理工大学 一种离子液体
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2008076948A (ja) 2006-09-25 2008-04-03 Konica Minolta Medical & Graphic Inc 感光性平版印刷版材料
US20110046125A1 (en) * 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
US7851489B2 (en) 2006-11-08 2010-12-14 Bristol-Myers Squibb Company Pyridinone compounds
KR20080045538A (ko) 2006-11-20 2008-05-23 에스케이케미칼주식회사 피리딘 화합물을 포함하는 염증 및 면역질환 치료용 약제조성물
CN1962642A (zh) 2006-11-21 2007-05-16 南开大学 具有除草活性的三氟甲基苯基哒嗪类衍生物及制备方法
GB0624105D0 (en) 2006-12-01 2007-01-10 Sterix Ltd Use
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
ES2383239T3 (es) 2006-12-14 2012-06-19 Astellas Pharma Inc. Compuestos de ácidos policíclicos útiles como antagonistas de CRTH2 y como agentes antialérgicos
CN101558075A (zh) 2006-12-14 2009-10-14 伊莱利利公司 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
CA2673299C (en) 2006-12-21 2016-04-12 Sloan-Kettering Institute For Cancer Research Pyridazinone compounds for the treatment of proliferative diseases
US7795249B2 (en) 2006-12-22 2010-09-14 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
ES2475193T3 (es) 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101235030A (zh) 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
DE102007007751A1 (de) 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
WO2008106202A1 (en) 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
JP5134834B2 (ja) 2007-03-01 2013-01-30 東ソー株式会社 ５，５−二置換−３−ピロリン−２−オン誘導体の製造方法
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US8586619B2 (en) 2007-03-12 2013-11-19 Vm Therapeutics Llc Agents of calcium ion channel modulators
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
EP2137179B1 (en) 2007-03-15 2015-09-02 Merck Sharp & Dohme Corp. Pyridazinone derivatives useful as glucan synthase inhibitors
EP2136809A4 (en) 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
WO2008121407A1 (en) 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
EP2137184B1 (en) 2007-04-03 2013-05-08 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2008124575A1 (en) 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
TW200845988A (en) * 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
WO2008124582A1 (en) 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
US20100129933A1 (en) 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
WO2008144720A2 (en) 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
MX2007006349A (es) 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo proceso de sintesis para la obtencion de 5-metil-1-fenil-2-(ih)-piridona, composicion y uso de la misma.
WO2008147169A2 (es) 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Microemolsion conteniendo pirfenidona
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
WO2009011412A2 (en) 2007-07-13 2009-01-22 Eisai R & D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
EP2164487A1 (en) 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for neuropathic pain
JP2010533127A (ja) 2007-07-13 2010-10-21 コミッサリア ア レネルジー アトミーク エ オ ゼネルジ ザルタナテイヴ 神経因性疼痛のためのａｍｐａ受容体アンタゴニストおよびアルドースレダクターゼ阻害剤
SI2170864T1 (sl) 2007-07-17 2012-04-30 Bristol Myers Squibb Co Piridon gpr119g proteinsko povezani receptorski antagonisti
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
EP2174547B1 (en) 2007-08-10 2017-01-18 Kumiai Chemical Industry CO., LTD. Pest control agent composition and pest controlling method
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
CN101371833A (zh) 2007-08-23 2009-02-25 中南大学 1-芳基-2(1h)-吡啶酮类化合物在制备治疗皮肤瘙痒药物中的应用
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CN101652138B (zh) 2007-09-19 2011-07-06 中南大学 1-取代芳基-2（1h）-吡啶酮化合物的新医药用途
CN101121697A (zh) * 2007-09-20 2008-02-13 东北师范大学 一种多取代吡啶-2(1h)-酮类化合物的合成方法
WO2009054544A1 (en) 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
WO2009054543A1 (en) 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders
RU2010121763A (ru) 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Производные пиридазинона и ингибиторы р2х7 рецептора
WO2009060835A1 (ja) 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
JP2011504481A (ja) 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
CA2708780A1 (en) 2007-12-11 2009-06-18 Research Development Foundation Small molecules for neuronal differentiation of embryonic stem cells
US20100256191A1 (en) 2007-12-26 2010-10-07 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−ピリジノン化合物および癌についてのその使用
MX2010008382A (es) 2008-01-30 2010-11-25 Cephalon Inc Derivados de piperidina espirociclicos substituidos, como ligandos de receptores de histamina-3 (h3).
CA2714111A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1h-pyrrolo fused pyridones
EP2262501B1 (en) 2008-03-07 2014-08-13 Solanan, Inc. Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone
US8349864B2 (en) 2008-03-25 2013-01-08 New Mexico Technical Research Foundation Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009124119A2 (en) 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2009124553A2 (en) 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
CN102015682B (zh) 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
JP2011525924A (ja) 2008-06-25 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
EP2307379A2 (en) 2008-06-27 2011-04-13 Novartis AG Organic compounds
MX2011000392A (es) 2008-07-11 2011-03-01 Irm Llc 4-fenoxi-metil-piperidinas como moduladoras de la actividad de gpr119.
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US20110166124A1 (en) 2008-07-23 2011-07-07 Mccormick Kevin D Tricyclic spirocycle derivatives and methods of use
PE20110368A1 (es) 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
JP2012500850A (ja) 2008-08-25 2012-01-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
CA2736970A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivatives for use as medicaments
CN102256966B (zh) 2008-10-17 2016-02-10 白头生物医学研究所 可溶性mTOR复合物和其调节剂
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
WO2010048716A1 (en) 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
CA2746220A1 (en) 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
US20110237622A1 (en) 2008-12-10 2011-09-29 Merck Frosst Canada Ltd. Renin inhibitors
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
CA2772760A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP5632857B2 (ja) 2009-01-07 2014-11-26 ヘンケル コーポレイションＨｅｎｋｅｌ Ｃｏｒｐｏｒａｔｉｏｎ 過酸化水素錯体および嫌気性接着剤の硬化システムにおけるそれらの使用
AU2010206543A1 (en) 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
JP2012516847A (ja) * 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
NZ594851A (en) 2009-02-05 2013-10-25 Takeda Pharmaceutical Pyridazinone compounds
WO2010104818A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2405913A1 (en) 2009-03-09 2012-01-18 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US20100266717A1 (en) 2009-04-20 2010-10-21 Marrone Bio Innovations, Inc. Chemical and biological agents for the control of molluscs
WO2010107816A2 (en) 2009-03-16 2010-09-23 Promega Corporation Nucleic acid binding dyes and uses therefor
CN106478496A (zh) 2009-03-27 2017-03-08 阿迪生物科学公司 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
AU2010241742A1 (en) 2009-04-27 2011-11-17 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
JP2012131708A (ja) 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
CA2761009A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
WO2010132864A1 (en) 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma
EP2474533B1 (en) 2009-05-25 2015-02-25 Central South University Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications
WO2010135972A1 (zh) 2009-05-25 2010-12-02 中南大学 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途
WO2010141592A2 (en) 2009-06-02 2010-12-09 Marquette University Chemical fragment screening and assembly utilizing common chemistry for nmr probe introduction and fragment linkage
US20120077795A1 (en) 2009-06-03 2012-03-29 Glaxsmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
EP2437601A4 (en) 2009-06-03 2012-10-31 Glaxosmithkline Llc BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
US20120077794A1 (en) 2009-06-03 2012-03-29 Glaxsmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
TWI434833B (zh) 2009-06-03 2014-04-21 Intermune Inc 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法
US20120083489A1 (en) 2009-06-03 2012-04-05 Christensen Iv Siegfried Benjamin Bis-pyridylpyridones as melanin-concentrating hormone receptor antagonists
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
WO2011077711A1 (ja) 2009-12-22 2011-06-30 興和株式会社 新規な２－ピリドン誘導体及びこれを含有する医薬
MX2012011460A (es) * 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
CA2812043A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Pyrimidinedione anti-viral compounds
JP5826261B2 (ja) 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
KR20120011357A (ko) * 2010-07-23 2012-02-08 현대약품 주식회사 치환된 피리디논 유도체 및 이의 제조방법
EP2604260B1 (en) * 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
US8643700B2 (en) * 2010-11-17 2014-02-04 Dell Products L.P. 3D content adjustment system
JP2013544854A (ja) 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
CN102558147B (zh) * 2010-12-23 2014-09-17 江苏先声药物研究有限公司 化合物、制备方法及应用
KR101928505B1 (ko) 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
KR101925971B1 (ko) 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2012107831A1 (en) 2011-02-11 2012-08-16 Signa S.A. De C.V. Method of making a pyridone compound, 5-ethyl-1-phenyl-2-(1h)-pyridone, and intermediates thereof
JP2014507474A (ja) 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
FI20115234A0 (fi) * 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
HK1197159A1 (en) 2011-05-25 2015-01-09 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
WO2012163356A1 (en) * 2011-05-27 2012-12-06 Jensen Denmark A/S A method and a feeder for feeding pieces of cloth
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
WO2012175514A1 (en) 2011-06-21 2012-12-27 Bayer Intellectual Property Gmbh Pyridinone derivatives and pharmaceutical compositions thereof
EP2729007A1 (de) * 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013018685A1 (ja) 2011-07-29 2013-02-07 東レ株式会社 ラクタム誘導体及びその医薬用途
CN102276616B (zh) * 2011-08-04 2013-09-04 中国科学院长春应用化学研究所 一种呋喃[3,2-c]吡啶-4(5H)-酮类化合物合成方法
CN104023725B (zh) 2011-08-16 2019-04-26 卡迪欧拉有限公司 控释制剂
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
BR112014013136B1 (pt) * 2011-11-30 2020-05-26 F. Hoffmann-La Roche Ag Novos derivados de dihidroisoquinolina-1-ona biciclicos
HUE053994T2 (hu) 2012-03-01 2021-08-30 Array Biopharma Inc Szerin/treonin kináz inhibitorok
WO2013142390A1 (en) 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
JP6501264B2 (ja) 2012-07-24 2019-04-17 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US20140094456A1 (en) 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
JP6256187B2 (ja) 2014-05-14 2018-01-10 株式会社デンソー 判定帰還型等化器

Also Published As

Publication number Publication date
RS61225B1 (sr) 2021-01-29
TWI734049B (zh) 2021-07-21
IL277341A (en) 2020-10-29
US20190321343A1 (en) 2019-10-24
HK1212981A1 (en) 2016-06-24
PE20211501A1 (es) 2021-08-11
PH12015500735B1 (en) 2015-06-01
US9359379B2 (en) 2016-06-07
EA027120B1 (ru) 2017-06-30
US20180064692A1 (en) 2018-03-08
CO7350637A2 (es) 2015-08-10
AU2018204894A1 (en) 2018-07-26
CA2884251C (en) 2022-07-05
HRP20201934T1 (hr) 2021-04-16
MX392621B (es) 2025-03-24
EP2903991A1 (en) 2015-08-12
EA201590477A1 (ru) 2015-09-30
TWI644898B (zh) 2018-12-21
CA3147961A1 (en) 2014-04-10
US10898474B2 (en) 2021-01-26
HUE051581T2 (hu) 2021-03-01
TW201414716A (zh) 2014-04-16
NZ707083A (en) 2018-08-31
BR112015006341A2 (pt) 2017-07-04
SA515360217B1 (ar) 2017-06-18
ECSP15017109A (es) 2016-01-29
IL237629B (en) 2020-09-30
UA120908C2 (uk) 2020-03-10
BR112015006341B1 (pt) 2022-05-31
KR20150064746A (ko) 2015-06-11
AR092742A1 (es) 2015-04-29
ES2835331T3 (es) 2021-06-22
AU2013327505A1 (en) 2015-04-30
CN104822687A (zh) 2015-08-05
PL2903991T3 (pl) 2021-03-08
SI2903991T1 (sl) 2021-01-29
JP6744355B2 (ja) 2020-08-19
CA2884251A1 (en) 2014-04-10
SG11201501751RA (en) 2015-04-29
DK2903991T3 (da) 2020-10-19
CN104822687B (zh) 2018-11-02
MX2020010037A (es) 2022-05-26
EA201790137A1 (ru) 2017-11-30
PE20151415A1 (es) 2015-10-16
CR20150225A (es) 2015-06-11
US20160263090A1 (en) 2016-09-15
KR102277608B1 (ko) 2021-07-15
MX375381B (es) 2025-03-06
TW201925174A (zh) 2019-07-01
WO2014055548A1 (en) 2014-04-10
PT2903991T (pt) 2020-12-15
LT2903991T (lt) 2020-12-28
JP2018135356A (ja) 2018-08-30
EA034171B1 (ru) 2020-01-14
MX2015003918A (es) 2015-08-05
NZ745814A (en) 2019-05-31
IL237629A0 (en) 2015-04-30
CA3296379A1 (en) 2026-03-02
KR102176667B1 (ko) 2020-11-10
US10376497B2 (en) 2019-08-13
ZA201502457B (en) 2021-09-29
US9675593B2 (en) 2017-06-13
KR20200130480A (ko) 2020-11-18
MY174897A (en) 2020-05-20
JP2016500661A (ja) 2016-01-14
JP6326053B2 (ja) 2018-05-16
IL277341B2 (en) 2023-06-01
IL270414B (en) 2021-09-30
AU2018204894B2 (en) 2020-05-21
PH12015500735A1 (en) 2015-06-01
US20150266899A1 (en) 2015-09-24
AU2013327505B2 (en) 2018-04-19
EP2903991A4 (en) 2016-09-07
CN108503575A (zh) 2018-09-07
EP2903991B1 (en) 2020-09-16
US20140107110A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CL2015000816A1 (es) Compuestos derivados de piridinonas; composicion farmaceutica; un metodo para tratar una condicion fibrotica.
BR112014032116A2 (pt) método.
BR112014010197A2 (pt) composto, composição farmacêutica, método de tratamento de um distúrbio
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
CL2014003318A1 (es) Un método para el fraccionamiento de lignina: fraccion de lignina.
BR112016011065A2 (pt) Composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BR112013030423A2 (pt) método para produção de biocoque
EP2704649A4 (en) TRINGLE FOR TENDONS OF QUADRICEPS
PL2613861T3 (pl) Ulepszony sposób SMB
BR112014006702A2 (pt) método para tratar osteoporose
HUE043139T2 (hu) Új SMB eljárás
BR112014031896A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um distúrbio
DK2741763T3 (da) Sammensætning til kontrolleret ovariestimulering.
CL2014002622A1 (es) Un metodo para modificar beta-estuco utilizando acido dietilen-triamin-pentaacetico.
BR112013018945A2 (pt) processo para a preparação de 4-amino-5-fluoro-3-halo-6-(substituído)picolinatos.
CL2014001960A1 (es) Metodo para producir una composición que contiene galacto-oligosacáridos.
BR112014031899A8 (pt) composto, composição farmacêutica, e, método para tratamento de um distúrbio
BR112013022820A2 (pt) método de tratamento
IL238507A0 (en) Butadiene extraction process
FI20115204L (fi) Menetelmä kemikaalien talteenottamiseksi
BR112013031360A2 (pt) método para produzir um composto, e, composto
BR112013019798A2 (pt) composições bakuchiol para tratamento de hiperpigmentação pós-inflamatória.
CL2015000590A1 (es) Método para recuperar oro.
PT2890272T (pt) Armário, método para fabricar um armário
ZA201502126B (en) New anti-invasive compounds